William Blair Issues Pessimistic Outlook for ANRO Earnings

Alto Neuroscience, Inc. (NYSE:ANRO) – Stock analysts at William Blair cut their Q3 2025 earnings per share (EPS) estimates for shares of Alto Neuroscience in a research report issued to clients and investors on Thursday, August 14th. William Blair analyst M. Minter now forecasts that the company will post earnings per share of ($0.64) for the quarter, down from their prior estimate of ($0.56). The consensus estimate for Alto Neuroscience’s current full-year earnings is ($2.54) per share. William Blair also issued estimates for Alto Neuroscience’s Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.46) EPS, Q1 2026 earnings at ($0.64) EPS, Q2 2026 earnings at ($0.64) EPS, Q3 2026 earnings at ($0.50) EPS, Q4 2026 earnings at ($0.51) EPS, FY2026 earnings at ($2.26) EPS, FY2027 earnings at ($2.26) EPS, FY2028 earnings at ($3.12) EPS and FY2029 earnings at ($1.64) EPS.

Other equities research analysts have also issued reports about the company. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Alto Neuroscience in a report on Thursday, June 26th. Wedbush reiterated a “neutral” rating and set a $4.00 price target on shares of Alto Neuroscience in a report on Thursday, May 15th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $8.50.

Alto Neuroscience Stock Up 1.0%

Shares of Alto Neuroscience stock opened at $3.15 on Monday. The firm has a market cap of $85.30 million, a price-to-earnings ratio of -1.32 and a beta of 1.84. The company has a debt-to-equity ratio of 0.18, a current ratio of 18.43 and a quick ratio of 18.43. Alto Neuroscience has a 52-week low of $1.60 and a 52-week high of $15.04. The stock has a 50-day simple moving average of $2.70 and a 200-day simple moving average of $2.72.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Wednesday, August 13th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.08).

Institutional Investors Weigh In On Alto Neuroscience

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. lifted its holdings in Alto Neuroscience by 73.1% in the 4th quarter. Point72 Asset Management L.P. now owns 1,692,153 shares of the company’s stock worth $7,158,000 after purchasing an additional 714,461 shares during the last quarter. Armistice Capital LLC lifted its holdings in Alto Neuroscience by 1.5% in the 2nd quarter. Armistice Capital LLC now owns 1,624,000 shares of the company’s stock worth $3,573,000 after purchasing an additional 24,000 shares during the last quarter. Marshall Wace LLP lifted its holdings in Alto Neuroscience by 9.9% in the 2nd quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock worth $2,062,000 after purchasing an additional 84,417 shares during the last quarter. Vestal Point Capital LP increased its position in Alto Neuroscience by 40.8% in the 4th quarter. Vestal Point Capital LP now owns 915,000 shares of the company’s stock worth $3,870,000 after buying an additional 265,000 shares during the period. Finally, AWM Investment Company Inc. increased its position in Alto Neuroscience by 31.1% in the 1st quarter. AWM Investment Company Inc. now owns 901,984 shares of the company’s stock worth $1,948,000 after buying an additional 214,153 shares during the period.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.